The new cell-based manufacturing facility is part of the company's over $2 billion capital investment in Australia, including the new plasma fractionation facility and global headquarters in Melbourne.
CSL Seqirus achieves major milestone in the construction of new facility
May 22, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New survey reveals most see living with COVID-19 as the 'new normal'
June 9, 2023 - - Latest News -
Industry leaders join Biointelect's new executive strategy panel
June 9, 2023 - - Latest News -
NZ patients welcome biosimilar but disappointed at failure to expand access
June 9, 2023 - - Latest News -
BMS welcomes 'One-Stop Shop' for clinical trials as an important step
June 9, 2023 - - Latest News -
The 'Week in Review' Podcast - 9 June
June 8, 2023 - - Podcast -
AVITA Medical announces US approval of RECELL for full thickness skin defects
June 8, 2023 - - Australian Biotech -
New report reveals 'crippling' impact of double dispensed quantities
June 8, 2023 - - Latest News